Imugene Secures Chinese Patent For Oncolytic Virotherapy CF33

Imugene Ltd (ASX: IMU) has received a notice of grant from the Chinese Patent Office protecting its oncolytic virotherapy CF33, following earlier grants in Japan and South Korea.

The company’s shares gained ~9% intra-day following the announcement, trading at A$0.073.

The patent titled “CHIMERIC POXVIRUS COMPOSITION AND USES THEREOF” protects the method of composition and method of use of CF33 to the year 2037.

CF33 is a chimeric vaccinia poxvirus from the lab of inventor Professor Yuman Fong, Chair of Sangiacomo Family Chair in Surgical Oncology at City of Hope, and a noted expert in the oncolytic virus field.

Step forward

Oncolytic viruses are designed to both selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.

The Chinese patent will protect CF33, including VAXINIA (CF33-hNIS) and CHECKvacc (CF33-hNIS-antiPDL1).

Imugene MD and CEO Leslie Chong said:

“Imugene receiving these patent grants for the CF33 family of oncolytic viruses is a crucial step forward and with China, Japan, and South Korea being the largest healthcare markets in Asia, this is a particularly important patent milestone.”

 onCARlytics Phase 1 clinical trial

 Last month, the clinical-stage immuno-oncology company achieved further progress with its Phase 1 clinical trial of its CD19 oncolytic virotherapy drug candidate onCARlytics.

The clinical trial has cleared its first cohort within the intratumoural monotherapy arm of the study and is ready to start combination dosing solid tumour patients with CD19 targeting drug blinatumomab (Blincyto® marketed by Amgen).

Known as OASIS, the first-in-class clinical trial targets adult patients with advanced or metastatic solid tumours.

The trial aims to evaluate the safety and efficacy of two routes of administration, intratumoural (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.

Cashed up

At the end of the December 31 2023 quarter, Imugene had $139.4 million in cash or equivalents, providing a runway to support its clinical pipeline and operations.

Net cash used in operating activities for the quarter amounted to $24.2 million.

Articles of Interest